Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $51.91, moving +1.29% from the previous trading session. This change lagged the S&P 500's 2.11% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 2.96%.
Shares of the specialty pharmaceutical company witnessed a loss of 7.19% over the previous month, trailing the performance of the Medical sector with its gain of 3.98% and the S&P 500's gain of 3.08%.
Market participants will be closely following the financial results of Amphastar Pharmaceuticals in its upcoming release. The company is predicted to post an EPS of $0.87, indicating a 19.18% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $174.9 million, indicating a 29.54% increase compared to the same quarter of the previous year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Amphastar Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Amphastar Pharmaceuticals holds a Zacks Rank of #3 (Hold).
In terms of valuation, Amphastar Pharmaceuticals is presently being traded at a Forward P/E ratio of 13.59. This expresses no noticeable deviation compared to the average Forward P/E of 13.59 of its industry.
We can additionally observe that AMPH currently boasts a PEG ratio of 0.6. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Generic Drugs industry was having an average PEG ratio of 1.45.
The Medical - Generic Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 187, finds itself in the bottom 26% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
